Characterization of human cancer xenografts in humanized mice.
immunology
oncology
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
accepted:
21
02
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
1
9
2021
Statut:
ppublish
Résumé
Preclinical evaluation of drugs targeting the human immune system has posed challenges for oncology researchers. Since the commercial introduction of humanized mice, antitumor efficacy and pharmacodynamic studies can now be performed with human cancer cells within mice bearing components of a human immune system. However, development and characterization of these models is necessary to understand which model may be best suited for different agents. We characterized A375, A549, Caki-1, H1299, H1975, HCC827, HCT116, KU-19-19, MDA-MB-231, and RKO human cancer cell xenografts in CD34 We found that CD4 These data demonstrate that there are tumor-intrinsic factors that influence the immune cell repertoire within tumors and spleen, and that TIL frequencies are a key factor in determining response to anti-PD-L1 in tumor xenografts in humanized mice. These data may also aid in the selection of tumor models to test antitumor activity of novel immuno-oncology or tumor-directed agents.
Sections du résumé
BACKGROUND
Preclinical evaluation of drugs targeting the human immune system has posed challenges for oncology researchers. Since the commercial introduction of humanized mice, antitumor efficacy and pharmacodynamic studies can now be performed with human cancer cells within mice bearing components of a human immune system. However, development and characterization of these models is necessary to understand which model may be best suited for different agents.
METHODS
We characterized A375, A549, Caki-1, H1299, H1975, HCC827, HCT116, KU-19-19, MDA-MB-231, and RKO human cancer cell xenografts in CD34
RESULTS
We found that CD4
CONCLUSIONS
These data demonstrate that there are tumor-intrinsic factors that influence the immune cell repertoire within tumors and spleen, and that TIL frequencies are a key factor in determining response to anti-PD-L1 in tumor xenografts in humanized mice. These data may also aid in the selection of tumor models to test antitumor activity of novel immuno-oncology or tumor-directed agents.
Identifiants
pubmed: 32217760
pii: jitc-2019-000416
doi: 10.1136/jitc-2019-000416
pmc: PMC7174072
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors are full-time employees and shareholders of Incyte.
Références
Blood. 2003 Nov 1;102(9):3302-10
pubmed: 12869510
Genome Med. 2015 Nov 20;7:118
pubmed: 26589293
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
Trends Immunol. 2018 Sep;39(9):748-763
pubmed: 30077656
Gut. 2018 Oct;67(10):1845-1854
pubmed: 29602780
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Cancer Lett. 2014 Mar 1;344(1):13-19
pubmed: 24513265
Int Immunol. 2009 Jul;21(7):843-58
pubmed: 19515798
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Breast Cancer Res. 2018 Sep 5;20(1):108
pubmed: 30185216
Cancer Res. 2016 Nov 1;76(21):6153-6158
pubmed: 27587540
Annu Rev Med. 2014;65:185-202
pubmed: 24188664
Nat Rev Cancer. 2018 Mar;18(3):139-147
pubmed: 29326431
Cancer Immunol Res. 2019 Aug;7(8):1267-1279
pubmed: 31186248
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Nat Commun. 2016 Dec 23;7:13898
pubmed: 28008921
FASEB J. 2018 Mar;32(3):1537-1549
pubmed: 29146734
Front Immunol. 2018 Feb 02;9:152
pubmed: 29456539